{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T09:03:21Z","timestamp":1766048601371},"reference-count":49,"publisher":"The Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,11,1]]},"abstract":"<jats:p>This study was designed to differentiate the contributions of hyperandrogenism, insulin resistance (IR), and body weight to the development of endothelial dysfunction in polycystic ovary syndrome and determine the effectiveness of insulin sensitization and antiandrogenic therapy after the establishment of vascular and metabolic dysfunction using a rat model of polycystic ovary syndrome. We hypothesized that the observed endothelial dysfunction was a direct steroidal effect, as opposed to changes in insulin sensitivity or body weight. Prepubertal female rats were randomized to the implantation of a pellet containing DHT or sham procedure. In phase 1, DHT-exposed animals were randomized to pair feeding to prevent weight gain or metformin, an insulin-sensitizing agent, from 5 to 14 weeks. In phase 2, DHT-exposed animals were randomized to treatment with metformin or flutamide, a nonsteroidal androgen receptor blocker from 12 to 16 weeks. Endothelial function was assessed by the vasodilatory response of preconstricted arteries to acetylcholine. Serum steroid levels were analyzed in phase 1 animals. Fasting blood glucose and plasma insulin were analyzed and homeostasis model assessment index calculated in all animals. Our data confirm the presence of endothelial dysfunction as well as increased body weight, hypertension, hyperinsulinemia, and greater IR among DHT-treated animals. Even when normal weight was maintained through pair feeding, endothelial dysfunction, hyperinsulinemia, and IR still developed. Furthermore, despite weight gain, treatment with metformin and flutamide improved insulin sensitivity and blood pressure and restored normal endothelial function. Therefore, the observed endothelial dysfunction is most likely a direct result of hyperandrogenism-induced reductions in insulin sensitivity, as opposed to weight gain.<\/jats:p>","DOI":"10.1210\/en.2015-1159","type":"journal-article","created":{"date-parts":[[2015,8,31]],"date-time":"2015-08-31T17:00:46Z","timestamp":1441040446000},"page":"4071-4080","source":"Crossref","is-referenced-by-count":38,"title":["Hyperandrogenism and Insulin Resistance, Not Changes in Body Weight, Mediate the Development of Endothelial Dysfunction in a Female Rat Model of Polycystic Ovary Syndrome (PCOS)"],"prefix":"10.1210","volume":"156","author":[{"given":"Amanda","family":"Hurliman","sequence":"first","affiliation":[{"name":"Division of Reproductive Endocrinology and Infertility (A.H., J.K.B., P.C.), University of Vermont, Burlington, Vermont 05405"},{"name":"Oregon Reproductive Medicine (A.H.), Portland, Oregon 97210"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Keller Brown","sequence":"first","affiliation":[{"name":"Division of Reproductive Endocrinology and Infertility (A.H., J.K.B., P.C.), University of Vermont, Burlington, Vermont 05405"},{"name":"Northeastern Reproductive Medicine (J.K.B., P.C.), Colchester, Vermont 05446"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Maille","sequence":"first","affiliation":[{"name":"Department of Obstetrics\/Gynecology and Reproductive Sciences (N.M., M.M., G.O.), University of Vermont, Burlington, Vermont 05405"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Mandala","sequence":"first","affiliation":[{"name":"Department of Obstetrics\/Gynecology and Reproductive Sciences (N.M., M.M., G.O.), University of Vermont, Burlington, Vermont 05405"},{"name":"Department of Cell Biology (M.M.), University of Calabria, Arcavacata di Rende (Cosenza) 87030, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Casson","sequence":"first","affiliation":[{"name":"Division of Reproductive Endocrinology and Infertility (A.H., J.K.B., P.C.), University of Vermont, Burlington, Vermont 05405"},{"name":"Northeastern Reproductive Medicine (J.K.B., P.C.), Colchester, Vermont 05446"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Osol","sequence":"first","affiliation":[{"name":"Department of Obstetrics\/Gynecology and Reproductive Sciences (N.M., M.M., G.O.), University of Vermont, Burlington, Vermont 05405"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"80","published-online":{"date-parts":[[2015,8,31]]},"reference":[{"key":"2020071612123221900_B1","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-14-0253","article-title":"The polycystic ovary syndrome: a position statement from the European Society of Endocrinology","volume":"171","author":"Conway","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"2020071612123221900_B2","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1210\/jc.2009-2724","article-title":"Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society","volume":"95","author":"Wild","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612123221900_B3","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1253\/circj.CJ-08-1169","article-title":"Endothelial dysfunction: the first step toward coronary arteriosclerosis","volume":"73","author":"Vanhoutte","year":"2009","journal-title":"Circ J"},{"key":"2020071612123221900_B4","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1161\/01.CIR.0000089191.72957.ED","article-title":"Endothelial function testing as a biomarker of vascular disease","volume":"108","author":"Verma","year":"2003","journal-title":"Circulation"},{"key":"2020071612123221900_B5","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1748-1716.2009.01964.x","article-title":"Endothelial dysfunction and vascular disease","volume":"196","author":"Vanhoutte","year":"2009","journal-title":"Acta Physiol (Oxf)"},{"key":"2020071612123221900_B6","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/0735-1097(95)00327-4","article-title":"Close relation of endothelial function in the human coronary and peripheral circulations","volume":"26","author":"Anderson","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"2020071612123221900_B7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1365-2265.2012.04490.x","article-title":"Endothelial function measured using flow-mediated dilation in polycystic ovary syndrome: a meta-analysis of the observational studies","volume":"78","author":"Sprung","year":"2013","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612123221900_B8","doi-asserted-by":"crossref","first-page":"5088","DOI":"10.1210\/jc.2005-0151","article-title":"Predictors of endothelial dysfunction in young women with polycystic ovary syndrome","volume":"90","author":"Kravariti","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612123221900_B9","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1161\/01.CIR.103.10.1410","article-title":"Polycystic ovary syndrome is associated with endothelial dysfunction","volume":"103","author":"Paradisi","year":"2001","journal-title":"Circulation"},{"key":"2020071612123221900_B10","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2265.2006.02645.x","article-title":"Severe endothelial dysfunction in young women with polycystic ovary syndrome is only partially explained by known cardiovascular risk factors","volume":"65","author":"Sorensen","year":"2006","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2020071612123221900_B11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1210\/jcem.87.2.8199","article-title":"Altered vascular function in young women with polycystic ovary syndrome","volume":"87","author":"Kelly","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612123221900_B12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1042\/CS20080218","article-title":"A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome","volume":"116","author":"Moran","year":"2009","journal-title":"Clin Sci (Lond)"},{"key":"2020071612123221900_B13","doi-asserted-by":"crossref","first-page":"R219","DOI":"10.1530\/REP-14-0435","article-title":"Adipose tissue dysfunction, adipokines, and low-grade chronic inflammation in polycystic ovary syndrome","volume":"149","author":"Spritzer","year":"2015","journal-title":"Reproduction"},{"key":"2020071612123221900_B14","doi-asserted-by":"crossref","first-page":"4927","DOI":"10.1210\/en.2011-1424","article-title":"Endothelial dysfunction in a rat model of PCOS: evidence of increased vasoconstrictor prostanoid activity","volume":"152","author":"Keller","year":"2011","journal-title":"Endocrinology"},{"key":"2020071612123221900_B15","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1210\/en.2007-0168","article-title":"A new rat model exhibiting both ovarian and metabolic characteristics of polycystic ovary syndrome","volume":"148","author":"Manneras","year":"2007","journal-title":"Endocrinology"},{"key":"2020071612123221900_B16","first-page":"H714","article-title":"Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts","volume":"266","author":"Verma","year":"1994","journal-title":"Am J Physiol"},{"key":"2020071612123221900_B17","doi-asserted-by":"crossref","first-page":"E1269","DOI":"10.1152\/ajpendo.90207.2008","article-title":"Validation of simple indexes to assess insulin sensitivity during pregnancy in Wistar and Sprague-Dawley rats","volume":"295","author":"Cacho","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071612123221900_B18","doi-asserted-by":"crossref","first-page":"E1023","DOI":"10.1152\/ajpendo.00397.2009","article-title":"Comparison between surrogate indexes of insulin sensitivity\/resistance and hyperinsulinemic euglycemic clamp estimates in rats","volume":"297","author":"Muniyappa","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071612123221900_B19","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/BF00280883","article-title":"Homeostasis model assessment: insulin resistance and \u03b2-cell function from fasting plasma glucose and insulin concentrations in man","volume":"28","author":"Matthews","year":"1985","journal-title":"Diabetologia"},{"key":"2020071612123221900_B20","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1042\/CS20130186","article-title":"Endothelial dysfunction in hyperandrogenic polycystic ovary syndrome is not explained by either obesity or ectopic fat deposition","volume":"126","author":"Sprung","year":"2014","journal-title":"Clin Sci (Lond)"},{"key":"2020071612123221900_B21","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1016\/j.fertnstert.2006.05.038","article-title":"Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome","volume":"86","author":"Dokras","year":"2006","journal-title":"Fertil Steril"},{"key":"2020071612123221900_B22","doi-asserted-by":"crossref","first-page":"E304","DOI":"10.1210\/jc.2010-1290","article-title":"Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance","volume":"96","author":"Manneras-Holm","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612123221900_B23","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.tem.2007.07.003","article-title":"Abdominal adiposity and the polycystic ovary syndrome","volume":"18","author":"Escobar-Morreale","year":"2007","journal-title":"Trends Endocrinol Metab"},{"key":"2020071612123221900_B24","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.mce.2008.10.035","article-title":"Androgen metabolism in adipose tissue: recent advances","volume":"301","author":"Blouin","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"2020071612123221900_B25","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1210\/jc.2004-0395","article-title":"Adipose tissue as an endocrine organ","volume":"89","author":"Kershaw","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612123221900_B26","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1161\/01.ATV.19.3.546","article-title":"PPAR\u03b3 activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR\u03b3 as a potential mediator in vascular disease","volume":"19","author":"Marx","year":"1999","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2020071612123221900_B27","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1161\/01.RES.85.5.394","article-title":"Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway","volume":"85","author":"Delerive","year":"1999","journal-title":"Circ Res"},{"key":"2020071612123221900_B28","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1161\/CIRCULATIONAHA.104.475673","article-title":"Peroxisome proliferator-activated receptors as transcriptional nodal points and therapeutic targets","volume":"115","author":"Brown","year":"2007","journal-title":"Circulation"},{"key":"2020071612123221900_B29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1530\/EJE-09-0733","article-title":"Metformin: an old medication of new fashion: evolving new molecular mechanisms and clinical implications in polycystic ovary syndrome","volume":"162","author":"Diamanti-Kandarakis","year":"2010","journal-title":"Eur J Endocrinol"},{"key":"2020071612123221900_B30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.2337\/diabetes.55.02.06.db05-1064","article-title":"Activation of the AMP-activated kinase by antidiabetes drug metformin stimulates nitric oxide synthesis in vivo by promoting the association of heat shock protein 90 and endothelial nitric oxide synthase","volume":"55","author":"Davis","year":"2006","journal-title":"Diabetes"},{"key":"2020071612123221900_B31","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.2337\/diabetes.54.7.2179","article-title":"Metformin prevents high-glucose-induced endothelial cell death through a mitochondrial permeability transition-dependent process","volume":"54","author":"Detaille","year":"2005","journal-title":"Diabetes"},{"key":"2020071612123221900_B32","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijcard.2008.04.010","article-title":"Metformin inhibits TNF-\u03b1-induced I\u03baB kinase phosphorylation, I\u03baB-\u03b1 degradation and IL-6 production in endothelial cells through PI3K-dependent AMPK phosphorylation","volume":"134","author":"Huang","year":"2009","journal-title":"Int J Cardiol"},{"key":"2020071612123221900_B33","doi-asserted-by":"crossref","first-page":"5569","DOI":"10.2174\/138161212803307590","article-title":"Insulin resistance and polycystic ovary syndrome through life","volume":"18","author":"Diamanti-Kandarakis","year":"2012","journal-title":"Curr Pharm Des"},{"key":"2020071612123221900_B34","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1007\/s11695-013-1153-2","article-title":"Metabolic, behavioral, and reproductive effects of vertical sleeve gastrectomy in an obese rat model of polycystic ovary syndrome","volume":"24","author":"Ressler","year":"2014","journal-title":"Obes Surg"},{"key":"2020071612123221900_B35","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ejogrb.2006.09.009","article-title":"Nitric oxide and fibrinogen in polycystic ovary syndrome: associations with insulin resistance and obesity","volume":"133","author":"Nacul","year":"2007","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2020071612123221900_B36","doi-asserted-by":"crossref","first-page":"5592","DOI":"10.1210\/jc.2004-0751","article-title":"Endothelial dysfunction in young women with polycystic ovary syndrome: relationship with insulin resistance and low-grade chronic inflammation","volume":"89","author":"Tarkun","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612123221900_B37","doi-asserted-by":"crossref","first-page":"4588","DOI":"10.1210\/jc.2003-031867","article-title":"Early impairment of endothelial structure and function in young normal-weight women with polycystic ovary syndrome","volume":"89","author":"Orio","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612123221900_B38","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1530\/eje.1.01910","article-title":"Metformin administration improves endothelial function in women with polycystic ovary syndrome","volume":"152","author":"Diamanti-Kandarakis","year":"2005","journal-title":"Eur J Endocrinol"},{"key":"2020071612123221900_B39","doi-asserted-by":"crossref","first-page":"6072","DOI":"10.1210\/jc.2005-0965","article-title":"Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study","volume":"90","author":"Orio","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612123221900_B40","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.fertnstert.2010.06.058","article-title":"Effect of the insulin sensitizers metformin and pioglitazone on endothelial function in young women with polycystic ovary syndrome: a prospective randomized study","volume":"95","author":"Naka","year":"2011","journal-title":"Fertil Steril"},{"key":"2020071612123221900_B41","doi-asserted-by":"crossref","first-page":"471","DOI":"10.2337\/dc06-0618","article-title":"Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic ovary syndrome","volume":"30","author":"Meyer","year":"2007","journal-title":"Diabetes Care"},{"key":"2020071612123221900_B42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0026-0495(95)90062-4","article-title":"Insulin sensitivity and antiandrogenic therapy in women with polycystic ovary syndrome","volume":"44","author":"Diamanti-Kandarakis","year":"1995","journal-title":"Metabolism"},{"key":"2020071612123221900_B43","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1080\/09513590400004736","article-title":"Metformin versus flutamide in the treatment of metabolic consequences of non-obese young women with polycystic ovary syndrome: a randomized prospective study","volume":"19","author":"Sahin","year":"2004","journal-title":"Gynecol Endocrinol"},{"key":"2020071612123221900_B44","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1210\/jc.2002-021875","article-title":"Beyond adrenal and ovarian androgen generation: increased peripheral 5\u03b1-reductase activity in women with polycystic ovary syndrome","volume":"88","author":"Fassnacht","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612123221900_B45","doi-asserted-by":"crossref","first-page":"4682","DOI":"10.1210\/jc.2003-030617","article-title":"Early endocrine, metabolic, and sonographic characteristics of polycystic ovary syndrome (PCOS): comparison between nonobese and obese adolescents","volume":"88","author":"Silfen","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071612123221900_B46","volume-title":"Clincial Gynecologic Endocrinology and Infertility","author":"Fritz","year":"2011","edition":"8th ed"},{"key":"2020071612123221900_B47","first-page":"CD003053","article-title":"Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility","volume":"5","author":"Tang","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"2020071612123221900_B48","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1093\/humrep\/dep444","article-title":"Metformin influence on hormone levels at birth, in PCOS mothers and their newborns","volume":"25","author":"Carlsen","year":"2010","journal-title":"Hum Reprod"},{"key":"2020071612123221900_B49","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.fertnstert.2007.11.069","article-title":"Possible metformin effect on adrenal androgens during pretreatment and IVF cycle in women with polycystic ovary syndrome","volume":"91","author":"Kjotrod","year":"2009","journal-title":"Fertil Steril"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/156\/11\/4071\/8987975\/endo4071.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/156\/11\/4071\/8987975\/endo4071.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T19:30:35Z","timestamp":1594927835000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/156\/11\/4071\/2422789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8,31]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2015-1159","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8,31]]}}}